The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis-Reference-Cited by-同舟云学术

The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis

Published:2018-03-21 Issue:3 Volume:9 Page:963-971
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Mu Pan-wei^ORCID,Liu De-zhao,Lin Ying,Liu Dong,Zhang Fan,Zhang Yong-jun,Lin Shuo,Wang Lin-qin,Wang Man-man,Shu Jiong,Zeng Long-yi,Chen Yan-ming

Funder

5010 Clinical Research Projects of Sun Yat-sen University

the Science and Technology Plan Projects of Guangdong Province

the Key Special Projects of Medical and Health Collaborative Innovation of Guangzhou City

the Special Scientific Research Project of Guangzhou City

National Key R&D Program of China

General Program of National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-018-0404-6.pdf

Reference22 articles.

1. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13[Suppl 1]:1–68.

2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.

3. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement–executive summary. Endocr Pract. 2013;19:536–57.

4. Lavernia F. What options are available when considering starting insulin: premix or basal? Diabetes Technol Ther. 2011;13[Suppl 1]:S85–92.

5. Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr TA, et al. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin. 2010;26:1621–8.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C‐peptide index at 2 h post‐meal is a useful predictor of endogenous insulin secretory capacity and withdrawal from insulin therapy in subjects with type 2 diabetes;Diabetes, Obesity and Metabolism;2024-04-22

2. Predictive value of postprandial C-peptide for utilizing multiple daily injection therapy in type 2 diabetes;Endocrine;2024-04-15

3. The efficacy of switching basal–bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching;Diabetology International;2023-09-04

4. The relationship between postprandial C peptide-glucose ratio, beta-cell function and treatment success in type 2 diabetes mellitus;Demiroglu Science University Florence Nightingale Journal of Medicine;2021-08-01